But what exactly is KLOW
TD: Tardive Dyskinesia for total (+) active metabolites for tetrabenazine & deutetrabenazine Schneider et al (2021) Adapted from Diana (2007), Schneider et al (2021) & Cheung & Parmar (2022) References: Aminoff MJ (2021): Pharmacologic Management of Parkinsonism & Other Movement Disorders Chapter 28
Lars Holtug Siham Imani Jan Mller Mikkelsen Executive Board Jan Mller Mikkelsen, Chief Executive Officer Michael Wolff Jensen, Chief Legal Officer Scott Thomas Smith, Chief Financial Officer Anni Lotte Kirstine Pedersen, Chief Administration Officer External Auditors Deloitte Statsautoriseret Revisionspartnerselskab Weidekampsgade 6 DK-2300 Copenhagen S Statement by Management on the Annual Report The Board of Directors and the Executive Board have today considered and approved the annual report of Ascendis Pharma A/S for the financial year January 1 to December 31, 2025
Forst T, Michelson G, Diessel S, et al
Blood tests can help distinguish this condition from SLE
That is because there are multiple compounds which are classed as vitamin C